Follow-up of patients no. 13 and no. 41. (A) Patient no. 41. (Top) Sequence analysis of PCR products on days ^-7, ⁺93, and ⁺183 of imatinib therapy. ASO-PCR detected T315I on day ^-7, while conventional sequencing was negative. A mix of T315I and wild type (arrow) was detected on day ⁺93, the time of first documented complete cytogenetic response. On day ⁺183, only T315I was detected, while the patient remained in complete cytogenetic remission. (Bottom) Follow-up with quantitative and qualitative RT-PCR showed a gradual although not uninterrupted decrease of BCR-ABL transcripts and eventually complete molecular remission. (B) Patient no. 13. (Top) Sequence analysis of PCR products on days ^-18, ⁺175, and ⁺316 of imatinib therapy. ASO-PCR detected Q252H in the specimen from day ^-18. One hundred percent Q252H was detected on day ⁺175 (left chromatogram, arrow). On day ⁺326, a mix of Q252H and F359V was detected (arrows). Note that a small wild-type signal has reemerged in position 252. (Bottom) Follow-up with quantitative RT-PCR for BCR-ABL.